Abstract: Incretinbased therapies are not only effective in preventing hyperglycemia, but also have shown significant multiple organ protective effects in preclinical and clinical studies. The renoprotective mechanisms of glucoganlike peptide1 receptor agonist (GLP1RA) and dipeptidyl peptidase4 inhibitor (DPP4I) include diuresis, natriuresis, reducing podocyte damage, inhibiting inflammation, antioxidative stress, antifibrosis, improving endothelial function, reducing body weight and antihypertension. The results of several clinical trials suggest that incretin results in reductions in urine albumintocreatinine ratio, and GLP1RA is especially helpful in reducing renal and cardiac endpoint events in diabetic patients. This review will summarize the cardiorenal protective effects and mechanisms of incretinbased therapy,to provide basis for individual theraputic paradigm to doctors.

Key words: glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-IV inhibitors, diabetic kidney disease